[Levamisole therapy under different dermatological indications].
More than 180 patients were treated for immunostimulation with levamisole within three and a half years. The results were statistically evaluated in 128 subjects. A highly significant improvement was noted in 44 patients suffering from recurrent herpes simplex labialis, facialis and oralis. 14 patients with recurrent herpes genitalis, lumbalis and glutaealis only experienced a reduction of the recurrence frequency. Aphthae in 16 subjects became less frequent and pain was reduced. Levamisole should be tried in recalcitrant chronic candidoses and bacterial infections not responding to specific antibiotic treatment. Slight side effects are relatively frequent, but severe ones are only rarely observed.
D000328:Adult; D002177:Candidiasis / Q000188:drug therapy*; D002180:Candidiasis, Oral / Q000188:drug therapy; D002648:Child; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005148:Facial Dermatoses / Q000188:drug therapy; D005260:Female; D006560:Herpes Labialis / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence; D012871:Skin Diseases / Q000188:drug therapy*; D013281:Stomatitis, Aphthous / Q000188:drug therapy*
D007978:Levamisole
Levamisol-Therapie bei verschiedenen dermatologischen Indikationen.